Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases

Journal of Crohn's and Colitis

Volumn 8, Issue 9, 2014, Pages 927-935

  Sandborn, William J ^a   Hanauer, Stephen ^b   Van Assche, Gert ^c   Panés, Julián ^d   Wilson, Stephanie ^e   Petersson, Joel ^f   Panaccione, Remo ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e UNIVERSITY OF CALGARY   (Canada)

^f ABBVIE INC   (United States)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

Algorithms; Early diagnosis; Inflammatory bowel diseases; Outcome assessment; Prognosis

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER;

ALGORITHM; CROHN DISEASE; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM INFLAMMATION; DISEASE COURSE; DISEASE SEVERITY; ENDOSCOPY; HUMAN; INFLAMMATORY BOWEL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; ULTRASOUND; SYMPTOMATOLOGY; TREATMENT PLANNING; DISEASE MANAGEMENT; INFLAMMATORY BOWEL DISEASES;

ALGORITHMS; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; REMISSION INDUCTION;

EID: 84906790163     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.02.021     Document Type: Review

References (72)

1. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
2. Smolen J.S., Aletaha D., Bijlsma J.W., Breedveld F.C., Boumpas D., Burmester G., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
3. Weber M.A., Julius S., Kjeldsen S.E., Brunner H.R., Ekman S., Hansson L., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004, 363:2049-2051.
4. Diabetes Association American Standards of medical care in diabetes - 2013. Diabetes Care 2013, 36(Suppl. 1):S11-S66.
5. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28:1462-1536.
6. Cellier C., Sahmoud T., Froguel E., Adenis A., Belaiche J., Bretagne J.F., et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994, 35:231-235.
7. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011, 17:1415-1422.
8. Torres J., Billioud V., Sachar D.B., Peyrin-Biroulet L., Colombel J.F. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012, 18:1356-1363.
9. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
10. Gupta R.B., Harpaz N., Itzkowitz S., Hossain S., Matula S., Kornbluth A., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105.
11. Dignass A., Lindsay J.O., Sturm A., Windsor A., Colombel J.F., Allez M., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012, 6:991-1030.
12. Dignass A., Van Assche G., Lindsay J.O., Lemann M., Soderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
13. Schoepfer A.M., Vavricka S., Zahnd-Straumann N., Straumann A., Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis 2012, 6:412-418.
14. De Vos M., Dewit O., D'Haens G., Baert F., Fontaine F., Vermeire S., et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis. J Crohns Colitis 2012, 6:557-562.
15. D'Haens G., Ferrante M., Vermeire S., Baert F., Noman M., Moortgat L., et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2218-2224.
16. Jurgens M., Mahachie John J.M., Cleynen I., Schnitzler F., Fidder H., van Moerkercke W., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011, 9:421-427.
17. Chamouard P., Richert Z., Meyer N., Rahmi G., Baumann R. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:882-887.
18. Pineton de Chambrun G., Peyrin-Biroulet L., Lemann M., Colombel J.F. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7:15-29.
19. Panaccione R., Colombel J.F., Louis E., Peyrin-Biroulet L., Sandborn W.J. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis 2013, 19:1645-1653.
20. Colombel J.F., Rutgeerts P., Sandborn W.J., Yang M., Lomax K.G., Pollack P.F., et al. Deep remission predicts long-term outcomes for adalimumab-treated patients with Crohn's disease: data from EXTEND. Gut 2010, 59(Suppl. 3):A80. [Abstract OP371].
21. Rutgeerts P., Van Assche G., Sandborn W.J., Wolf D.C., Geboes K., Colombel J.F., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142:1102-1111.
22. Molander P., Sipponen T., Kemppainen H., Jussila A., Blomster T., Koskela R., et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD. J Crohns Colitis 2013, 7:730-735.
23. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
24. Prantera C., Marconi S. Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. Ther Adv Gastroenterol 2013, 6:137-156.
25. Candy S., Wright J., Gerber M., Adams G., Gerig M., Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
26. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995, 332:292-297.
27. Ford A.C., Sandborn W.J., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659.
28. Prefontaine E., Macdonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010, CD000545.
29. Bultman E., Kuipers E.J., van der Woude C.J. Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010, 32:313-323.
30. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
31. Van Assche G., Wolf D., D'Haens G., Sandborn W.J., Colombel J.F., Lazar A., et al. Reduced steroid usage in ulcerative colitis patients with week 8 response to adalimumab: subanalysis of ULTRA 2. Gut 2012, 61(Suppl. 3):A81. [Abstract OP350].
32. Panaccione R., Hibi T., Peyrin-Biroulet L., Schreiber S. Implementing changes in clinical practice to improve the management of Crohn's disease. J Crohns Colitis 2012, 6(Suppl. 2):S235-S242.
33. Romkens T.E., Kampschreur M.T., Drenth J.P., van Oijen M.G., de Jong D.J. High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis 2012, 18:2190-2198.
34. Lichtenstein G.R., Ramsey D., Rubin D.T. Randomised clinical trial: delayed-release oral mesalazine 4.8g/day vs. 2.4g/day in endoscopic mucosal healing - ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011, 33:672-678.
35. Travis S.P., Danese S., Kupcinskas L., Alexeeva O., D'Haens G., Gibson P.R., et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014, 63:433-441.
36. Actis G.C., Pellicano R., David E., Sapino A. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. Inflamm Allergy Drug Targets 2010, 9:6-9.
37. Solberg I.C., Vatn M.H., Hoie O., Stray N., Sauar J., Jahnsen J., et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007, 5:1430-1438.
38. Langholz E., Munkholm P., Davidsen M., Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992, 103:1444-1451.
39. Etchevers M.J., Aceituno M., Garcia-Bosch O., Ordas I., Sans M., Ricart E., et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis 2009, 15:1320-1325.
40. Louis E., Michel V., Hugot J.P., Reenaers C., Fontaine F., Delforge M., et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003, 52:552-557.
41. Allez M., Lemann M., Bonnet J., Cattan P., Jian R., Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002, 97:947-953.
42. Lakatos P.L., Czegledi Z., Szamosi T., Banai J., David G., Zsigmond F., et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol 2009, 15:3504-3510.
43. Dubinsky M.C. Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease. World J Gastroenterol 2010, 16:2604-2608.
44. Jess T., Simonsen J., Jorgensen K.T., Pedersen B.V., Nielsen N.M., Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30years. Gastroenterology 2012, 143:375-381.
45. Ullman T.A., Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140:1807-1816.
46. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
47. Travis S.P., Farrant J.M., Ricketts C., Nolan D.J., Mortensen N.M., Kettlewell M.G., et al. Predicting outcome in severe ulcerative colitis. Gut 1996, 38:905-910.
48. Haritunians T., Taylor K.D., Targan S.R., Dubinsky M., Ippoliti A., Kwon S., et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 2010, 16:1830-1840.
49. Carbonnel F., Lavergne A., Lemann M., Bitoun A., Valleur P., Hautefeuille P., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994, 39:1550-1557.
50. Alvarez-Lobos M., Arostegui J.I., Sans M., Tassies D., Plaza S., Delgado S., et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005, 242:693-700.
51. Hefti M.M., Chessin D.B., Harpaz N.H., Steinhagen R.M., Ullman T.A. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum 2009, 52:193-197.
52. Peyrin-Biroulet L., Harmsen W.S., Tremaine W.J., Zinsmeister A.R., Sandborn W.J., Loftus E.V. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol 2012, 107:1693-1701.
53. Vermeire S. Towards a novel molecular classification of IBD. Dig Dis 2012, 30:425-427.
54. Arijs I., Quintens R., Van Lommel L., Van Steen K., De Hertogh G., Lemaire K., et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010, 16:2090-2098.
55. Arijs I., Li K., Toedter G., Quintens R., Van Lommel L., Van Steen K., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009, 58:1612-1619.
56. Lee J.C., Lyons P.A., McKinney E.F., Sowerby J.M., Carr E.J., Bredin F., et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011, 121:4170-4179.
57. Kakkar A., Wasan S.K., Farraye F.A. Targeting mucosal healing in Crohn's disease. Gastroenterol Hepatol (N Y) 2011, 7:374-380.
58. Cruz P.D., Kamm M., Hamilton A., Ritchie K., Krejany S., Gorelik A., et al. Strategic timing of anti-TNF therapy in postoperative Crohn's disease: comparison of routine use immediately postoperatively with selective use after demonstrated recurrence at 6month endoscopy: results from POCER. United Eur Gastroenterol J 2013, 1(Suppl. 1):A16. [Abstract OP052].
59. Panes J., Bouzas R., Chaparro M., Garcia-Sanchez V., Gisbert J.P., Martinez de Guerenu B., et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011, 34:125-145.
60. Ordas I., Rimola J., Rodriguez S., Paredes J.M., Martinez-Perez M.J., Blanc E., et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology 2014, 146:374-382.
61. Van Assche G., Herrmann K.A., Louis E., Everett S.M., Colombel J.F., Rahier J.F., et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. J Crohns Colitis 2013, 7:950-957.
62. Garcia-Bosch O., Ordâs I., Rodriguez S., Ramirez A.M., Aceituno M., Ricart E., et al. Comparison of the impact of MRI and colonoscopy on management of Crohn's disease. Gastoenterology 2012, 142:S21-S22. [Abstract 90].
63. Neye H., Ensberg D., Rauh P., Peitz U., Monkemuller K., Treiber G., et al. Impact of high-resolution transabdominal ultrasound in the diagnosis of complications of Crohn's disease. Scand J Gastroenterol 2010, 45:690-695.
64. Horsthuis K., Bipat S., Bennink R.J., Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008, 247:64-79.
65. Ripolles T., Martinez M.J., Paredes J.M., Blanc E., Flors L., Delgado F. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy. Radiology 2009, 253:241-248.
66. Ordas I., Feagan B.G., Sandborn W.J. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut 2011, 60:1754-1763.
67. Sandborn W.J., Panaccione R., Thakker R., Lomax K.G., Chen N., Mulani P.M., et al. Duration of Crohn's disease affects mucosal healing in adalimumab-treated patients: results from EXTEND. J Crohns Colitis 2010, 4:S36. [Abstract PO69].
68. Schreiber S., Reinisch W., Colombel J.F., Sandborn W.J., Hommes D.W., Robinson A.M., et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013, 7:213-221.
69. Feagan B.G., Macdonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012, 10:CD000543.
70. Khan K.J., Dubinsky M.C., Ford A.C., Ullman T.A., Talley N.J., Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011, 106:630-642.
71. Lakatos P.L., Golovics P.A., David G., Pandur T., Erdelyi Z., Horvath A., et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012, 107:579-588.
72. Feagan B.G., Panaccione R., Sandborn W.J., D'Haens G.R., Schreiber S., Rutgeerts P.J., et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.